DIAGNOS Provides Update on Business Operations
Momentum Public Relations
Press Release: July 31 2018
Diagnos Inc.(ADK:V) (DGNOF:OTCQB), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an update on business operations.
We are happy to report these important milestones and accomplishments over the last twelve months:
- Signing of our first agreement with a Canadian hospital, the CHUM in Montreal. This hospital is now screening patients for diabetic retinopathy and hypertension. We expect to screen 4,500 patients from August to December of 2018. It is estimated that the diabetic population in Quebec is 800,000,
- Signing of a 3-year contract with our first customer in the USA after a successful pilot. We are currently screening an average of 600 patients per month and our customer is ordering additional cameras,
- First contract in Saudi Arabia with a local partner. We began with 100 patients screened per month and now we are averaging 1,000 per month,
- Working with pharmaceutical companies such as Novo Nordisk to broaden the use of our AI technology for the detection of Hypertension complications in the retina of the eye,
- Opening of our first of 15 clinics in Panama and a new provincial government state in Mexico. We have several new proposals in Latin America with many governments and clinics.
- Establishing a sales force to cover Latin America and the USA including existing international accounts. The Mexican government has temporarily stopped the mass screening program because of elections in Mexico. Now that the election results are known, we plan to restart the program soon.
CARDIO, our new Hypertension application announced recently, is a by-product of the work we are doing in the field of stroke prevention based on the analysis of the human vascular system. This new prevention tool is in clinical trial in the US, Canada, Algeria and Mexico. We are working with other hospitals and we expect to see more organisations collaborating with DIAGNOS in the development of CARDIO.
The Corporation is working at establishing a permanent team to cover the US market. The addition of a new US based board member, Dr. Reid Maclellan, is contributing to the business development efforts there. Dr. Maclellan, an Instructor of Surgery in the field of vascular anomalies at Harvard Medical School, will contribute to DIAGNOS’ growth in the US. Additionally we made changes at the board level in bringing new senior talent to improve corporate governance.
“The last year was a pivotal period for DIAGNOS. The AI market came alive in 2017. We believe this demonstrates that all the work done by our employees to become an early leader is finally benefiting the Corporation. For the last 2 years, DIAGNOS has been working with clients in 16 countries to establish a local presence and this proves that the use of AI in the medical field is really happening. In our opinion, the learning curve for any high tech company to be fully able to access the medical market is at least 5 years. We also strongly believe we’ve got the right timing with our AI solutions. Regulatory approvals such as FDA, Health Canada, CE mark, COFEPRIS plus others and the proof of concept have been successfully achieved at DIAGNOS,’’ said André Larente, President and CEO of DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
Robots Predicted to be Performing 85% of surgeries by 2025
Momentum Public Relations
Blog: July 11, 2018
AI Medical Diagnosis APP Gets Better Exam Mark Than Doctors
Exploding AI Medical Market Predicted to Hit US$12.15 Billion by 2023
Robots Predicted to be Performing 85% of surgeries by 2025
On June 28, 2018, Forbes ran a story with the headline reading, “This AI Just Beat Human Doctors on a Clinical Exam MD.”
The story by Parmy Olson, tells how an artificial intelligence application created by Babylon Health scored on a standard British test designed to grade the diagnostic ability of doctors in training. For the last five years the average passing grade has been 72%. Babylon Health’s artificial intelligence powered software performed ten points above the average coming in at 82%.
At the beginning of 2018 Research House Frost & Sullivan made some predictions. The one that perhaps best defines future shock is that by 2025, 85% of surgical procedures are likely to be done by robots. Over the next two to three years Frost & Sullivan also predict that AI platforms in medical imaging will increase productivity by 10-15%.
Babylon Health was founded five years ago and has raised US$85 million for research and development. Babylon has developed an intriguing mix of AI and human diagnosis that could if adopted drive down overall health care costs by using its diagnostic apps to pre-screen patients and suggest what’s wrong, while leaving the final diagnosis in the hands of a living breathing MD.
While at first this may seem like an episode of Star Trek, the service is real enough. The company’s largest and most important client to date is the British National Health Service which has allowed 26 thousand patients to transfer from the standard GP based service to Babylon. Another 20,000 are on a waiting list.
In a typical scenario a Babylon patient will describe symptoms to a diagnostic engine which will then suggest a probable diagnosis. Then there is the video call between doctor and patient. While the interview is going on the app automatically records and transcribes the interview. The patients face is analyzed to determine if he or she is feeling confused, worried or normal, according to the movements of 117 muscles located in the nose, lips or eyebrows. At the end of the consultation the live doctor will, if necessary send a prescription to the patients pharmacy.
The software also creates a digital twin of the patient and the company believes the twin will be used to determine what medical problems will develop in the future. All of this should help make healthcare timelier and more affordable.
Babylon’s business model is to sell its services to health care providers such as government Medicare systems or health insurance companies. The company also sells its consulting service to individuals and offers access to software that individuals can use to investigate an ailment. Babylon intends to launch in the US, during 2019.
Forbes sums up recent market activity like this, “Investment in the AI medical market is pouring in, from tech giants like IBM’s Watson, Alphabet and Philips to pharmaceutical companies and swiftly proliferating start-ups. The market for artificial intelligence in health care and the life sciences is projected to grow by 40 percent a year, to $6.6 billion in 2021, according to estimates from Frost & Sullivan.”
In March of this year research house Mordor Intelligence predicted that by 2023 the global artificial intelligence in medicine market would reach US$ 12.15 Billion. The report, Artificial Intelligence in Medicine Market-by Application and Geography-Growth, Trends, and forecasts (2018-2023) details how AI is moving into the medical workplace providing faster and more efficient medical care.
While AI can be used to manage patient records and other types of data the real payoff for AI in medical applications comes in reducing human error. When AI systems have been used in image labelling, error rates have been reduced from 28.5% to 2.5%.
According to Mordor, the artificial intelligence in medicine market will grow from US$1.6 billion in 2017 to US$12.5 billion by 2023, a CAGR of 40.15% from 2018 to 2023. A number of factors are driving the market and can be divided into two categories. On the one hand there is the increased efficiency which AI systems offer providing a more efficient diagnosis. This also applies to patient data management. Both of these, better diagnosis and better data management, will help drive down the cost of medical treatment.
The flip side of the coin is the high cost of error. According to the Mordor report preventable medical mistakes result in roughly 210,000 deaths per year. Diagnostic mistakes account for roughly 440,000 deaths per year. And finally, medical mistakes cost the healthcare industry approximately US$1 trillion per year.
As well as the companies listed above other key players developing artificial intelligence and deep learning medical applications include: Intel; Microsoft, Siemens and General Electric.
With a market value that is growing at 40% CAGR a year, the AI in medical applications market is a developing sector that retail investors should take a good look at. It is a market driven by demographic factors, as the baby boomers continue to age they will require more medical attention, and efficiency. Any technology that cuts medical costs will be highly valued.
While there are no sure bets in the stock market, one AI diagnosis company that you should take a look at is the Montreal-based Diagnos. Diagnos has specialized in developing a proprietary technology, CARA, computer assisted retinal analysis that uses enhanced retinal digital images to detect the initial stages of diabetic retinopathy.
The retina is at the back of the eye and it is the only place where doctors can observe veins and arteries and detect early diabetes. Diabetes can lead to blindness if untreated and early detection can prevent 85-90% of vision loss. The process is simple. An image of the eye is taken and then image can then be analyzed.
CARA has been used to diagnose 222,034 patients at last count, in 16 countries, using 131 screening sites. In early June, The Montreal Gazette ran a story on Diagnos’ setting up its first Canadian pilot project at the Centre hospitalier de l’Universite de Montreal (CHUM). Diagnos is a company on the move and with its shares, (TSXV: ADK) closing at $0.06 on July 10, 2018, an attractive entry point into the explosive AI medical market.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FULL DISCLOSURE: Diagnos is a paid client of Momentum PR.
- Published in Blog
DIAGNOS Installs its First Retina Screening Clinic based on Artificial Intelligence in Panama
Momentum Public Relations
Press Release: July 10 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the installation of its first retina AI screening clinic, in the Panama’s private health sector.
“We are delighted to open our first of 15 Medical clinics in Panama in collaboration with DIAGNOS,” said the CEO and owner of these clinics. He also added: “We encourage and support DIAGNOS in its endeavor as an AI pioneer in the early detection of critical health issues, such as diabetic retinopathy. We are also looking forward to the upcoming release of the hypertension application.”
“We are looking forward to a long term relationship with our new customer in Panama. We have been working with their team to establish a marketing strategy to support their growth objectives. We are anticipating a substantial growth in the number of patients to screen,” said Guillermo Moreno, Vice-President at DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tél. : 450 678-8882, poste 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Broadens its Collaboration with the Government of Mexico
Momentum Public Relations
Press Release: July 4 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an expansion of its screening services with the Mexican government in one northern state of Mexico. As per the agreement, DIAGNOS plans to screen 10,000 patients by December 31, 2018.
“In Mexico, a large portion of our government’s budget and expenses is going towards the medical treatment of two major problems for our patients’ health; diabetes and hypertension. Our objective is to collaborate with DIAGNOS in order to provide a preventive and a better way of monitoring our patients health”, said the Chief Medical Officer of the state. The Chief Medical Officer of the state also added: “We strongly believe that this preventive approach will strongly benefit our patients and generate substantial savings in future healthcare costs”.
The project consists of the screening of 10,000 patients by December 31, 2018, with a vision to extend the project for the following years. “We have been working with the diabetes team at the state level, and are able to provide the right solution at the right time”, said Guillermo Moreno, Vice-President at DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tél. : 450 678-8882, poste 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
Albert Mining Announces New Gold Discoveries on the Ashuanipi Property, Labrador, Quebec Using Artificial Intelligence (AI)
Momentum Public Relations
Press Release: May 31 2018
Albert Mining Inc. (“Albert Mining” or “Corporation”) (TSX-V: AIIM), a mining exploration company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques in the mining sector, is pleased to announce historical 2013 exploration results for the 100%-owned Ashuanipi property (283 claims). The project is located 30 km west of Schefferville, along the Quebec-Labrador border.
The Ashuanipi gold project was generated in 2012 using CARDS (Computer Aided Resources Detection System) for 2282726 Ontario Ltd. The current property corresponds in most part to two former claim blocks held by 2282726 Ontario Ltd. until 2015. In the summer of 2013, the later had mandated Diagnos Inc. to conduct exploration work for gold on its CARDS’s prospective targets. The campaign returned 12 samples with assay values above 1 g/t Au and 128 with values above 0.1 g/t Au. The three most significant results originated from newly discovered outcrops and yielded assays of 17.45, 12.25, and 8.13 g/t Au. The 17.45 g/t Au value was obtained from a one meter wide quartz vein while other elevated results were mainly encountered within the silicate facies horizon (pyrigarnite) of iron formation lenses. Albert Mining staked the current Ashuanipi property on January10, 2018.
The above information was taken from an unpublished exploration report prepared by Diagnos Inc. for 2282726 Ontario Ltd. and dated January 20, 2014.
Mr. Michel Fontaine, President & CEO at Albert Mining, stated: “Artificial Intelligence has proven successful again and demonstrated it can reduce exploration time and costs significantly by decreasing the surface area to be investigated by 95% to 97%. These recently released historical results, along with the presence of several gold occurrences identified previously in the area, encourage Albert Mining to pursue exploratory work over its Ashuanipi property. In this regard, a high-resolution heliborne magnetic survey which would serve to guide future exploration programs and a structural analysis and synthesis of the entire property area are considered necessary to better understand all the geological features controlling gold mineralization.”
About Albert Mining Inc. – Powered by Artificial Intelligence (AI)
Albert is a junior mining exploration company using Artificial Intelligence (AI) with an extensive portfolio of gold, copper and zinc properties in Quebec. Albert also recently acquired all assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert can count on a multidisciplinary team that includes professionals in geophysics, geology, AI, and mathematics. The Company’s objective is to develop a new royalty stream by significantly enhancing and participating in the exploration success rate of mining.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Fax: 613-422-0773
Email: michel@albertmining.com
Website: www.albertmining.com
Albert Mining-Powered by Artificial Intelligence
Additional information about the Company is available under Albert Mining’s profile on SEDAR atwww.sedar.com .
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or are events or conditions that “will”, “would”, “may”, “could” or “should” occur or be achieved. This news release contains forward-looking statements, pertaining to, among other things, the following: the resumption of the trading of Albert shares on the TSX Venture Exchange. Statements regarding future production, capital expenditures and development plans are subject to all of the risks and uncertainties normally incident to the exploration for and development and production of oil and gas that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These risks include, but are not limited to, inflation or lack of availability of goods and services, environmental risks, drilling risks, regulatory changes and certain other known and unknown risks detailed from time to time in Albert Mining’s public disclosure documents, copies of which are available on Albert Mining’s SEDAR profile at www.sedar.com .
Although Albert Mining believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. Albert Mining’s actual results may differ materially from those expressed or implied in forward-looking statements and readers should not place undue importance or reliance on the forward-looking statements. Statements including forward-looking statements are made as of the date they are given and except as required by applicable securities laws, Albert Mining disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
- Published in Albert Mining
Albert Mining Inc. Acquires 9 Mining Titles at lac Guillaume close to Shefferville, Quebec
Momentum Public Relations
Press Release: March 20 2018
Albert Mining Inc . (“Albert” or “Corporation”) (TSX-V: AIIM), a mining exploration company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques in the mining sector, is pleased to announce the signing of a purchase agreement with 9248-7792 Quebec Inc. (“seller”) to acquire nine mining titles at Lac Guillaume, 30 km west of Shefferville in the province of Quebec.
Under the terms of the agreement, Albert will issue 150,000 common shares of its share capital to the seller, at a deemed price of $0.075 per share, in payment for the acquisition of the assets and will grant a 1% NSR. Albert may, at any time, buy back 0.5% NSR by paying $500,000 to the seller. Should the seller receive an offer from a third party to purchase the full or a portion of the NSR, Albert must be immediately notified in writing and must receive a copy of the offer. Albert will have the right of first refusal within 60 days following reception of the offer or buy back the NSR as per the terms and conditions stipulated in the offer received from the third party.
The transaction is subject to terms and conditions such as receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange. All monies quoted in this news release shall be stated and paid in lawful money of Canada.
About Albert Mining Inc.
Albert is a junior mining exploration company with an extensive portfolio of gold, copper and diamond properties in Quebec. Albert also recently acquired assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, and mathematics. The Company’s objective is to develop a new royalty stream by significantly enhancing and participating in the exploration success rate of mining.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Fax: 613-422-0773
Email: michel@albertmining.com
Website: www.albertmining.com
Albert Mining-Powered by Artificial Intelligence
Additional information about the Company is available under Albert’s profile on SEDAR at www.sedar.com .
- Published in Albert Mining
DIAGNOS Announces the Opening of a Screening Clinic at Chaparral’s Health Management Wellness Center for Medicare Beneficiaries
Momentum Public Relations
Press Release: March 14 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the opening of a third eye screening clinic in California located at Chaparral Medical Group Health Management Wellness Center.
In 2010, Medicare launched an annual benefit to all their members at Chaparral’s Health Management Wellness Center. The goal is to help promote preventive care methods, emphasizing on how to prevent disease instead of treating disease. With that, Chaparral Medical Group has decided it will automatically include eye screening using our CARA platform for diabetic and pre-diabetic patient at their annual visit.
“Chaparral is introducing AI to enhance the overall value of the annual health examination to Medicare members by encompassing CARA as an additional screening test for the annual wellness program. It is estimated that Medicare currently has 44 million beneficiaries enrolled in the Medicare program, some 15 percent of U.S. population. Having Chaparral Medical Group as a trusted partner will help to deploy faster while meeting all the industry requirements,” said Yves-Stephane Couture, VP sales at DIAGNOS.
“By adding eye screening with retina anomalies detection, we are broadening our study for annual wellness visits. As DIAGNOS continues to develop new algorithms and detect more illness, it will significantly help us to prevent disease evolution and take early action. We are proud to use DIAGNOS’ state of the art technology and to benefit from the Artificial Intelligence in our daily fight against diseases and we look forward to using them at the Health Management Centre,” said Dr. Jeereddi Prasad MD, Diabetes Specialist, President, and Medical Director of Chaparral Medical Group.
About Chaparral Medical Group
Chaparral Medical Group is a 80 physicians multi-specialty group serving the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on our FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Daniel Renaud or Thomas Renaud, Managing Directors |
DIAGNOS Inc. | Arrowhead Business and Investment Decisions, LLC |
Tel: 450-678-8882 ext. 224 | Tel: +1 212 619 6889, ext. 7010 |
alarente@diagnos.ca | diagnos@arrowheadbid.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
Following a successful year, DIAGNOS Announces a One-Year Agreement in United Arabs Emirates with a Major Pharmaceutical Company
Momentum Public Relations
Press Release: March 7 2018
DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a follow-up contract by signing a turnkey one-year screening contract in United Arabs Emirates.
So far, DIAGNOS’ healthcare services have been rendered in 16 countries worldwide. During the period covered by the agreement, we estimate that an additional 2,500 patients will be screened in UAE using our CARA platform.
“We are excited to continue our collaboration with this large pharmaceutical company. More and more we, DIAGNOS and our pharmaceutical partner, are working at educating governments around the world to our Wellness Program (CARA) and demonstrating the benefits and cost savings that can be attained from it. We are continuing to implement our growth strategy with our existing pharmaceutical partner,” said Yves-Stéphane Couture, DIAGNOS Vice-President of sales.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on our FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Daniel Renaud or Thomas Renaud, Managing Directors |
DIAGNOS Inc. | Arrowhead Business and Investment Decisions, LLC |
Tel: 450-678-8882 ext. 224 | Tel: +1 212 619 6889, ext. 7010 |
alarente@diagnos.ca | diagnos@arrowheadbid.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
Relevium Appoints Mr. Didier Martin as Blockchain Lead Expert
Momentum Public Relations
Press Release: March 5 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF) and (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce it has appointed Mr. Didier Martin as special advisor and project leader for the Company’s current and future Blockchain projects.
Mr. Didier Martin joins the company effective immediately in his advisory capacity to provide technical leadership over the Company’s current and future Blockchain Technology projects, including advising on all strategic aspects of a potential Token Security Offering (TSO), the integration and positioning of the technology into the Tagspire joint venture and developing use cases for Relevium including the development of a supply chain security private Blockchain solution for the company’s online business.
Aurelio Useche, CEO stated: “In a growing and competitive space like health and wellness, we need to be nimble and able to adopt new technology. Blockchain and Artificial Intelligence are examples of useful and applicable technologies we can integrate to provide a competitive advantage to our business”. Mr. Useche stated further: “We can either take a lead and open ourselves today to the blue-sky that these technologies can provide, OR we can become followers and late adopters. The choice to us is very clear”
Mr. Didier Martin serves currently as Lead Expert at Interblockchain.io, a solution capable of interconnecting heterogeneous Blockchain allowing free cryptocurrencies movements between Bitcoin, Bitcoin Cash, Litecoin, Ethereum, Neo, EOS and his experience is well aligned to provide a solid ground for the Company’s plans in this space. Mr. Martin has 30 years’ experience in the management of technology, security and software development. Mr. Martin has also held senior executive roles in several start-ups, public companies and consortiums.
Aurelio Useche, CEO stated: “We are honoured to have Didier as our Blockchain lead expert. Our entire team extends a warm welcome to Mr. Martin and look forward to identifying opportunities and use cases for our business”
The appointment of a Blockchain expert solidifies Relevium’s commitment to accomplish everything set forth in the H2 guidance and to ensure the best talent and partners within the industry, as the Company continues to grow its business.
About Blockchain Technology
Blockchain is a transparent and incorruptible digital ledger that can be applied to any transaction of value. This digital ledger is a dynamic growing list of records (blocks) linked to each other and encrypted for security. In addition to security, Blockchain enables the use of smart contracts, which are self-automated computer programs that can carry out the terms of any contract or transaction. Blockchain is the underlying technology behind cryptocurrencies.
“…the most critical area where Blockchain helps is to guarantee the validity of a transaction by recording it not only on a main register but a connected distributed system of registers, all of which are connected through a secure validation mechanism.” Ian Khan, TEDx Speaker, Author and Technology Futurist
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
Relevium Technologies Inc.
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
After Successful Screening of 2,500 patients as part of a Pilot Project with Kanhoor Medical Co, DIAGNOS will Now Screen 35,000 patients in the Kingdom of Saudi Arabia
Momentum Public Relations
Press Release: February 27 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a positive conclusion to multiple pilots project by signing a three-year contract with Kanhoor Medical Co. (Kanhoor) in the kingdom of Saudi Arabia.
Diabetes mellitus is one of the largest global health crisis of the 21st century and a major public health problem in Saudi Arabia in parallel with the worldwide diabetes pandemic. The prevalence of diabetes is progressing strongly year after year in this country. Diabetes is now present in much younger age group, which in turn will most likely result in growth of Diabetic Retinopathy (DR). As per the World Health Organization (WHO), Saudi Arabia ranks seventh in the world for diabetes. Approximately seven (7) million of the population in Saudi Arabia are diabetic and around three (3) million are pre-diabetic. This represents a pool of ten (10) million patients in need of being screened yearly for DR.
For the past 10 months, DIAGNOS and Kanhoor teams have worked diligently on four pilots. In partnership with Al Kahhal Medical Complex, the first two successful pilots were in Dammam and AL-Hasha in the eastern province of Saudi Arabia. We just completed our third pilot in Riyadh at the Shaqra General Hospital and we now are screening patients at the prestigious King Faisal Hospital.
The results were convincing and generated a very positive endorsement from the medical team involved. Kanhoor has agreed to extend its agreement with DIAGNOS for three years. “Our objective is to screen every diabetic patient in the Kingdom with CARA in extending the services to the private health sector, NGO’s and in the public system as well. “Our short term objective is to screen 35,000 in the coming year. We’re in discussions with other health providers with our neighbouring countries in the Middle East so they can also benefit from early detection,” said Rashid Al Mugait, president of Kanhoor.
In order to support this new service, we are announcing the creation of grading centre in Dammam. The grading centre will use DIAGNOS AI (Artificial Intelligence) technology to support its activity and it will be connect virtually to all the screening clinics of Kanhoor Medical Go. “Right at the screening site, at risk patients will know right away if additional treatments are needed to protect their vision. The solution will help us to screen more patients and at lower cost. The patients will gain a better access to care to avoid risks, delay and undue stress for them and their families,“ said Dr Abdulaziz Rushood from Al Kahhal Medical Complex. Dr Rushood is an ophthalmologist, vitreo retinal surgeon and Assistant Professor at King Fahd University Hospital.
“This announcement by Kanhoor is very strategic for the growth of DIAGNOS in Saudi Arabia, the Gulf region and the Middle-East. We now have a highly technical savvy partner with strong ties in the market to sell our technology in this region of 22 countries. By creating a grading center in Saudi Arabia, we will strengthen our collaboration with this medical community and tremendously increase the efficiency of the screening process to benefit the patients,” said Yves-Stéphane Couture, DIAGNOS Vice-President of sales.
About Kanhoor Medical Co:
Al Kanhoor is focusing on telemedicine in KSA providing technology for remote patients observation, marketing Diagnos suite of products in KSA and beyond. Al Kanhoor is a sister company of HAJZTELECOM “HTC” Technology & Telecom solutions provider and contractor to Saudi Telecom -STC- contractor since 1997.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Daniel Renaud or Thomas Renaud, Managing Directors |
DIAGNOS Inc. | Arrowhead Business and Investment Decisions, LLC |
Tel: 450-678-8882 ext. 224 | Tel: +1 212 619 6889, ext. 7010 |
alarente@diagnos.ca | diagnos@arrowheadbid.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
- 1
- 2